Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present as part of the CEO Spotlight event at the 2026 Georgia Life Sciences Summit. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, convenes leaders from biotechnology, medical technology, research, manufacturing, and investment sectors. Sheridan's presentation will highlight the company's lead product under development, AVERSA™, an abuse-deterrent transdermal technology designed to incorporate aversive agents into patches to help prevent abuse, diversion, misuse, and accidental exposure involving drugs with abuse potential.
This presentation comes at a critical time when the opioid crisis continues to challenge public health systems. According to the Centers for Disease Control and Prevention, drug overdose deaths remain a leading cause of injury-related death in the United States. Technologies like AVERSA™ are part of a broader effort to mitigate the risks associated with prescription opioids. By making it more difficult to extract and abuse the active ingredients in patches, such technologies aim to reduce the potential for misuse while maintaining therapeutic benefits for patients in legitimate need of pain management.
Nutriband's participation in the summit underscores its position at the forefront of pharmaceutical innovation. The company's AVERSA™ technology can be incorporated into any transdermal patch, offering a versatile solution for drugs with abuse potential. This approach not only addresses fentanyl but could be applied to other opioids and stimulants, potentially expanding the market for safer drug delivery systems. The summit provides a platform for Nutriband to engage with key stakeholders, including potential partners and investors, furthering its mission to bring this technology to market.
The Georgia Life Sciences Summit is a premier event for the life sciences community in the Southeast, attracting industry experts, researchers, and policymakers. Nutriband's presence highlights the growing interest in abuse-deterrent formulations as a regulatory and public health priority. With the U.S. Food and Drug Administration encouraging the development of abuse-deterrent opioids, companies like Nutriband are poised to play a significant role in shaping the future of pain management.
For those interested in learning more about Nutriband and its developments, the company's website offers additional information at www.nutriband.com. The latest news and updates regarding NTRB are available in the company's newsroom at https://ibn.fm/NTRB. Additionally, the full press release can be accessed at https://ibn.fm/Un3ax.
